During the first year of OA-07, patients received a second injection of either LOR or placebo. The second year involved a ...
Upadacitinib 15 mg plus a 26-week GC taper outperformed placebo in combination with a 52-week GC taper for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback